Autologous chondrocytes (ProChon Biotech)(Autologous chondrocytes (ProChon Biotech))

概要

基本信息

药物类型

细胞疗法

别名

BioCart、BioCartII

靶点-

作用机制

软骨替代物

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

非在研机构-

最高研发阶段批准上市

首次获批日期

希腊 (2009-12-07),

膝盖受伤

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

3

项与 Autologous chondrocytes (ProChon Biotech) 相关的临床试验

DRKS00003393 / RecruitingN/AIIT

Preoperative strength and sensorimotor training prior to autologous chondrocyte implantation of the knee joint - PREHACI

开始日期2012-06-15

申办/合作机构-

NCT00729716 / Unknown status临床2期

Phase II Study to Investigate the Efficacy and Safety of BioCart™II in the Treatment of Symptomatic Cartilage Defects of the Femoral Condyle in Comparison With Microfracture

BioCart™II is a novel scaffold seeded with autologous chondrocytes to be used to repair cartilage lesions of the knee. This study is designed to compare the efficacy and safety of BioCart™II treatment compared to microfracture which is the classical method of treatment.

开始日期2008-05-01

申办/合作机构

ProChon Biotech Ltd.

ISRCTN54356626 / CompletedN/AIIT

Autologous chondrocyte implantation (ACI) in the treatment of early Osteoarthritis (OA)

开始日期2003-09-02

申办/合作机构-

100 项与 Autologous chondrocytes (ProChon Biotech) 相关的临床结果

登录后查看更多信息

100 项与 Autologous chondrocytes (ProChon Biotech) 相关的转化医学

登录后查看更多信息

100 项与 Autologous chondrocytes (ProChon Biotech) 相关的专利（医药）

登录后查看更多信息

8

项与 Autologous chondrocytes (ProChon Biotech) 相关的文献（医药）

2022-12-16·Journal of Investigational Allergology and Clinical Immunology3区 · 医学

English

3区 · 医学

Article

作者: Soto-Retes, L ; López-Carrasco, V ; Merino-Bohórquez, V ; Cisneros Serrano, C ; Delgado Romero, J ; Domínguez-Ortega, J ; Blanco-Aparicio, M ; Ferrando Piqueres, R ; Díaz-Pérez, D

2021-04-01·International Orthopaedics2区 · 医学

Autologous chondrocytes versus filtered bone marrow mesenchymal stem/stromal cells for knee cartilage repair—a prospective study

2区 · 医学

Article

作者: Filardo, Giuseppe ; Drobnič, Matej ; Leban, Jure ; Barlič, Ariana ; Busacca, Maurizio ; Veber, Matija ; Martinčič, David

PURPOSETo document clinical, radiologic, and cellular data of a prospective patient series treated by a tri-layer collagen-hydroxyapatite biomimetic osteochondral scaffold (CHAS) intra-operatively seeded with cultivated autologous chondrocytes (AC) or with filtered bone marrow stem/stromal cells (fBMSC) to address chronic osteochondral knee lesions.METHODSThirty-six consecutive patients (15 to 59 years) with chronic osteochondral lesions (1.8-10 cm²) in the condylar or patellofemoral knee surfaces were enrolled. Lesions were covered with CHAS fixed with a fibrin glue. The superficial layer of CHAS was intra-operatively injected with active cells: in initial five patients, ACs were put directly onto dry CHAS (dry-AC); next, eight AC patients had CHAS moistened with cell culture media (media-AC), while the tourniquet was released allowing blood soaking of CHAS in the rest (14 blood-AC, 9 blood-fBMSC). Seventeen (50%) patients required different concomitant procedures. All patients were followed for serious adverse events (SAE) or graft failures; clinical, radiographic, and MRI evaluation was conducted. Cellular data on the injected cells were assessed.RESULTSAt a follow-up of 39 months (16-81), 17 patients required an additional surgical intervention: seven graft-related SAE (early post-operative synovitis and/or arthrofibrosis) were registered (3 dry-AC, 3 media-AC, 1 blood-fBMSC). There were two graft failures (1 dry-AC, 1 blood-fBMSC) for secondary reasons. All clinical scores significantly improved from pre- to post-operative values: IKCD subjective 44 to 65; IKDC examination (9/17/5/5) to (20/10/5/1); KOOS (P61/S59/ADL67/Sp32/QoL31) to (P79/S75/ADL84/Sp55/QoL51); Tegner activity scale 3.3 to 4.4. There was evidence of radiographic osteoarthritis progression-Kellgren-Lawrence 1.0 to 1.5. MOCART scores at the final follow-up averaged 71 (10 to 95). Graft-type analysis demonstrated an increased rate of graft-related SAE in dry-AC and media-AC, but their final outcomes were equivalent. Cellular data of AC at the implantation were as follows: cells in suspension 9.2 × 10⁶, viability 95%. In blood-fBMSC group, a cell suspension with 87% viability was injected, which contained 1156 CFU-Fs.CONCLUSIONCHAS with intra-operative seeding of active cells, either AC or fBMSC, led to an overall successful outcome for the treatment of chronic osteochondral lesions in the knee. Blood soaking of CHAS in situ before cell seeding significantly decreased early post-operative adverse events, such as synovitis and arthrofibrosis.

2015-12-01·Pediatric Research3区 · 医学

Repeated autologous umbilical cord blood infusions are feasible and had no acute safety issues in young babies with congenital hydrocephalus

3区 · 医学

Article

作者: Sun, Jessica M ; Fitzgerald, Anne ; Waters-Pick, Barbara ; Allison, June ; McLaughlin, Colleen ; Grant, Gerald A ; Kurtzberg, Joanne

BACKGROUNDBabies with congenital hydrocephalus often experience developmental disabilities due to brain injury associated with prolonged increased pressure on the developing brain parenchyma. Umbilical cord blood (CB) infusion has favorable effects in animal models of brain hypoxia and stroke and is being investigated in clinical trials of brain injury in both children and adults. We sought to establish the safety and feasibility of repeated intravenous infusions of autologous CB in young babies with congenital hydrocephalus.METHODSInfants with severe congenital hydrocephalus and an available qualified autologous CB unit traveled to Duke for evaluation and CB infusion. When possible, the CB unit was utilized for multiple infusions. Patient and CB data were obtained at the time of infusion and analyzed retrospectively.RESULTSFrom October 2006 to August 2014, 76 patients with congenital hydrocephalus received 143 autologous CB infusions. Most babies received repeated doses, for a total of two (n = 45), three (n = 18), or four (n = 4) infusions. There were no infusion-related adverse events. As expected, all babies experienced developmental delays.CONCLUSIONCryopreserved CB products may be effectively manipulated to provide multiple CB doses. Repeated intravenous infusion of autologous CB is safe and feasible in young babies with congenital hydrocephalus.

100 项与 Autologous chondrocytes (ProChon Biotech) 相关的药物交易

登录后查看更多信息

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
膝盖受伤	希腊	ProChon Biotech Ltd.	2009-12-07

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
膝盖受伤	临床2期	美国	ProChon Biotech Ltd.	-
Legg-Calve-Perthes病	临床1期	美国	ProChon Biotech Ltd.	2008-05-01
Legg-Calve-Perthes病	临床1期	以色列	ProChon Biotech Ltd.	2008-05-01